Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults | Zendy

Nicola Napoli | Zendy; Rocky Strollo | Zendy; Giuseppe Defeudis | Zendy; Gaetano Leto | Zendy; Chiara Moretti | Zendy; Simona Zampetti | Zendy; Luca D’Onofrio | Zendy; Giuseppe Campagna | Zendy; Andrea Palermo | Zendy; Valentina Greto | Zendy; Silvia Manfrini | Zendy; Mohammed I. Hawa | Zendy; Richard David Leslie | Zendy; Paolo Pozzilli | Zendy; Raffaella Buzzetti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults

Author(s) -

Nicola Napoli,

Rocky Strollo,

Giuseppe Defeudis,

Gaetano Leto,

Chiara Moretti,

Simona Zampetti,

Luca D’Onofrio,

Giuseppe Campagna,

Andrea Palermo,

Valentina Greto,

Silvia Manfrini,

Mohammed I. Hawa,

Richard David Leslie,

Paolo Pozzilli,

Raffaella Buzzetti

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-02274

Subject(s) - sclerostin , medicine , endocrinology , type 2 diabetes , n terminal telopeptide , diabetes mellitus , bone remodeling , body mass index , osteocalcin , chemistry , biochemistry , wnt signaling pathway , alkaline phosphatase , enzyme , gene

Bone formation is impaired in both type 1 diabetes and type 2 diabetes (T2D), whereas sclerostin, an antagonist of bone formation, is increased in T2D only. No data are available on latent autoimmune diabetes in adults (LADA), an autoimmune type of diabetes that may clinically resemble T2D at diagnosis. We evaluated serum sclerostin and bone turnover markers in LADA compared with those in T2D and whether metabolic syndrome (MetS) affects sclerostin in T2D or LADA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research